Recent Pfizer Press Releases

  • 6/20/17 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 1, 2017. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2017 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at
  • 6/19/17 8:00 am EDT

    An estimated 10 to 30 percent of pregnant women carry the GBS bacteria; 1 the vaccine candidate is being studied to help protect newborns from infection via maternal immunization

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection. In newborns, GBS manifests as sepsis, pneumonia, and meningitis,2 with potentially fatal outcomes for some, and long-lasting neurological damage in 46 to 50 percent of those infected.3 “Because their immune systems are stillmore...
  • 6/16/17 4:35 am EDT

    ORAL Strategy is the First Trial to Compare a JAK Inhibitor, XELJANZ, as Monotherapy or in Combination with Methotrexate (MTX) versus Humira ® (adalimumab) plus MTX

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today detailed results from ORAL Strategy, a head-to-head, noninferiority Phase 3b/4 study of XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) as monotherapy or in combination with methotrexate (MTX) compared to Humira® plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). ORAL Strategy also compared XELJANZ monotherapy to XELJANZ in combination with MTX. The study results were publishedmore...
  • 6/14/17 1:20 pm EDT

    Partnership with Basilea Reaffirms Pfizer’s Global Infectious Disease Commitment and Industry Leadership

    NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, today announced they have entered into an agreement whereby Pfizer will be granted the exclusive commercialization rights in Europe to CRESEMBA (isavuconazole), a novel anti-fungal treatment for adult patients with diagnosed invasive aspergillosismore...
  • 6/13/17 9:00 am EDT

    Pfizer and Parents Magazine Team Up to Educate Parents About a Serious Disease That Can Put a Child’s Life at Risk

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE), in partnership with Parents magazine (NYSE:MDP), announced today the results of a national survey of more than 2,000 new and expectant parents assessing their knowledge of childhood infectious diseases, such as measles, whooping cough and invasive pneumococcal disease (IPD), and the measures parents can take to help prevent them. Conducted online by Harris Poll, the survey found that parents were leastmore...
  • 6/13/17 8:00 am EDT
    • Global Phase 3 program is studying potential new treatment option for millions of people living with chronic pain associated with osteoarthritis and chronic low back pain
    • Acts in a different manner than opioids and other analgesics
    NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP). Tanezumab is an investigational humanized monoclonal antibody that selectively targets, binds to and inhibits nerve growth factor (NGF). It is the first NGF inhibitor tomore...
  • 6/10/17 1:00 pm EDT

    Ertugliflozin as Add-on to Metformin or in Initial Co-administration with Sitagliptin Showed Significant A1C Reductions in Adults with Type 2 Diabetes

    KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS MET and VERTIS SITA) of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes, met their primary endpoints. In the studies, both doses of ertugliflozin tested (5 mg and 15 mg daily) achieved statisticallymore...
  • 6/9/17 8:00 am EDT

    - Amendment accelerates anticipated PROSPER top-line results by two years -

    - Target sample size reduced to approximately 1,440 patients and estimated primary completion date is June 2017 -

    TOKYO & NEW YORK--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE:PFE) announced today the amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of XTANDI® (enzalutamide) in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC). The primary endpoint remains the same:more...
  • 6/7/17 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017 at 8:00 a.m. Pacific Daylight Time. To view and listen to the webcast, visit our web site at Information on accessing and pre-registering for the webcastmore...
  • 6/6/17 8:00 am EDT

    —Tafamidis, An Investigational Medicine for TTR-CM a Rare, Progressive and Fatal Disease, is Currently in Phase 3 Development—

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to tafamidis, the company’s investigational treatment for transthyretin cardiomyopathy (TTR-CM). This rare disease is associated with progressive heart failure and is universally fatal.1,2,3 Currently in Phase 3 clinical development for TTR-CM, tafamidis is being evaluated for its potential to reduce mortality and cardiovascularmore...